Search clinical trials for: CT-P13 SC Auto-injector

Total 259 results

Celltrion

Completed

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Moderately to Severely Active Rheumatoid Arthritis

Poland
Celltrion

Completed

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

Health, Subjective

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

Influenza

United States
Celltrion

Completed

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

Crohn's Disease

France, Turkey, Czechia, Greece, Latvia, Hungary, Belarus, Israel, United States, Spain, Bulgaria, Serbia, Croatia, Italy, Germany, India, Japan, Mexico, Moldova, Republic of, Peru, Poland, Romania, Russian Federation, Slovakia, South Africa and more
Celltrion

Completed

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

Ulcerative Colitis

Poland

This is a preview

Log in or create a free account to see all matching trials and use the full search.

Log in Register

Subscribe